Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Double-dummy, Placebo-controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole Extended Release (ER) Versus Placebo and Versus Pramipexole Immediate Release (IR) Administered Orally Over a 26-week Maintenance Phase in L-Dopa+ Treated Patients With Advanced Parkinsons Disease (PD)

Next Previous
X
Search
Trial Profile

A Double-blind, Double-dummy, Placebo-controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole Extended Release (ER) Versus Placebo and Versus Pramipexole Immediate Release (IR) Administered Orally Over a 26-week Maintenance Phase in L-Dopa+ Treated Patients With Advanced Parkinsons Disease (PD)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pramipexole (Primary) ; Pramipexole
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Boehringer Ingelheim

    • Most Recent Events

    • 14 Nov 2012 Planned number of patients changed from 516 to 645 as reported by European Clinical Trials Database (Parent trial: EudraCT2007-000074-23).
    • 17 Apr 2010 Results from the open-label phase following a switch from immediate-release to extended-release pramipexole presented at the 62nd Annual Meeting of the American Academy of Neurology
    • 23 Mar 2010 FDA has approved once-daily MIRAPEX ER for the treatment of idiopathic (early or late) parkinson's disease, according to a Boehringer Ingelheim media release. The FDA approval was supported by this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top